Skip to main content
Contact Us
Back to Homepage
follow us on linkedin
follow us on facebook
follow us on twitter
follow us on youtube
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Site Search
toggle main menu
News
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Normal
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
11/15/2016
Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus
11/03/2016
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results
10/19/2016
Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus
09/29/2016
Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy
09/07/2016
Marinus Appoints Seth H.Z. Fischer to its Board of Directors
08/09/2016
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results
06/28/2016
Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
06/27/2016
Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28
06/22/2016
Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
06/13/2016
Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
05/11/2016
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2015 Financial Results
05/03/2016
Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference
04/19/2016
Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus
04/15/2016
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus
04/12/2016
Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting
03/12/2016
Marinus Pharmaceuticals Provides Business Update and Reports Year End 2014 Financial Results
03/01/2016
Marinus Pharmaceuticals to Present at the Cowen & Company Annual Healthcare Conference
02/24/2016
Marinus Pharmaceuticals to Participate in Cowen & Company Annual Healthcare Conference
01/07/2016
Marinus Pharmaceuticals Hires Dr. Albena Patroneva as Chief Medical Officer